Trial Profile
A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone or in Combination With Durvalumab, Tremelimumab, and/or Docetaxel in Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2022
Price :
$35
*
At a glance
- Drugs MEDI 5083 (Primary) ; Docetaxel; Durvalumab; Tremelimumab
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca; MedImmune
- 24 Jul 2020 Status changed from active, no longer recruiting to completed.
- 13 Feb 2020 Planned End Date changed from 31 Dec 2020 to 1 May 2020.
- 13 Feb 2020 Planned primary completion date changed from 31 Dec 2020 to 1 May 2020.